Targets › FDPS
26 programs from 24 companies in 26 trials: 10 Phase 4, 7 Phase 1, 5 Phase 2, 4 Phase 3; Oncology, Metabolic and endocrine, Other; next expected readout Dec 2026.
Key enzyme in isoprenoid biosynthesis which catalyzes the formation of farnesyl diphosphate (FPP), a precursor for several classes of essential metabolites including sterols, dolichols, carotenoids, and ubiquinones. FPP also serves as substrate for protein farnesylation and geranylgeranylation. (UniProt, P14324)
Open in Phaseline: the race on FDPS, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Hospital for Special Surgery, New York | Risedronic Acid Farnesyl diphosphate synthase inhibitor | FDPS | Phase 4 | Osteogenesis Imperfecta | Jan 2027 |
| Aarhus University Hospital | Zoledronic Acid Anhydrous Farnesyl diphosphate synthase inhibitor | FDPS | Phase 4 | Osteoporosis, Postmenopausal | Feb 2027 |
| Shanghai Pulmonary Hospital, Shanghai, China | Vγ2Vδ2 T lymphocyte-based immunotherapy (zoledronic acid/interleukin 2) Drug combination that amplifies Vγ2Vδ2 T cells via zoledronic acid (FDPS inhibitor) and IL | IL2, FDPS | Phase 4 | MDR-TB | Aug 2027 |
| Wake Forest University Health Sciences | Alendronic Acid Farnesyl diphosphate synthase inhibitor | FDPS | Phase 4 | Bone Loss | Jan 2028 |
| University of Aarhus | Zoledronic acid Farnesyl diphosphate synthase inhibitor | FDPS | Phase 4 | Primary Hyperparathyroidism | Feb 2028 |
| Chinese University of Hong Kong | Alendronic Acid Farnesyl diphosphate synthase inhibitor | FDPS | Phase 4 | ACL Reconstruction | Jul 2028 |
| Hadassah Medical Organization | Zoledronic Acid Farnesyl diphosphate synthase inhibitor | FDPS | Phase 4 | HIV Infected Individuals | Dec 2028 |
| Odense University Hospital | Alendronic Acid Farnesyl diphosphate synthase inhibitor | FDPS | Phase 4 | Osteoporosis in Post-menopausal Women | Mar 2029 |
| National Taiwan University Hospital | Ibandronic Acid Farnesyl diphosphate synthase inhibitor | FDPS | Phase 4 | Postmenopausal Osteoporosis | Aug 2030 |
| National Taiwan University Hospital | Zoledronic Acid Farnesyl diphosphate synthase inhibitor | FDPS | Phase 4 | Postmenopausal Osteoporosis | Aug 2030 |
| UNICANCER | zoledronic acid Farnesyl diphosphate synthase inhibitor | FDPS | Phase 3 | Sarcoma | Dec 2026 |
| St. Louis University | Zoledronic Acid Farnesyl diphosphate synthase inhibitor | FDPS | Phase 3 | Giant Cell Tumor of Bone | Jan 2027 |
| Wake Forest University Health Sciences | Risedronic Acid Farnesyl diphosphate synthase inhibitor | FDPS | Phase 3 | Bone Loss | Apr 2028 |
| Sherief Abd-Elsalam | alendronate sodium Farnesyl diphosphate synthase inhibitor | FDPS | Phase 3 | Beta Blocker Toxicity | Oct 2030 |
| Australian and New Zealand Intensive Care Research Centre | Zoledronic Acid Farnesyl diphosphate synthase inhibitor | FDPS | Phase 2 | Critical Illness | Feb 2027 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Alendronic Acid Farnesyl diphosphate synthase inhibitor | FDPS | Phase 2 | HIV | Mar 2027 |
| University of California, Davis | Alendronate Sodium Farnesyl diphosphate synthase inhibitor | FDPS | Phase 2 | Sickle Cell Disease | Sep 2027 |
| Harbin Medical University | Risedronate Sodium Bisphosphonate; targets farnesyl diphosphate synthase (FDPS) in the mevalonate pathway to | FDPS | Phase 2 | Breast Cancer Triple Negative Breast Cancer | Mar 2028 |
| AUVA Traumazentrum Vienna Site UKH Meidling | Zoledronic Acid Farnesyl diphosphate synthase inhibitor | FDPS | Phase 2 | Orthopedics | Dec 2030 |
| University of Wisconsin, Madison | Zoledronic Acid Farnesyl diphosphate synthase inhibitor | FDPS | Phase 1 | Acute Myeloid Leukemia | Dec 2026 |
| Emory University | Zoledronic Acid Anhydrous Farnesyl diphosphate synthase inhibitor | FDPS | Phase 1 | Neuroblastoma | Dec 2026 |
| Institute of Hematology & Blood Diseases Hospital, China | zoledronic acid Farnesyl diphosphate synthase inhibitor | FDPS | Phase 1 | Congenital Dyserythropoietic Anemia (CDA) | Feb 2027 |
| Children's Hospital Medical Center, Cincinnati | Zoledronic Acid Anhydrous Farnesyl diphosphate synthase inhibitor | FDPS | Phase 1 | Hematopoietic Stem Cell Transplantation | Jan 2028 |
| Mohammed Milhem | Zoledronic Acid Farnesyl diphosphate synthase inhibitor | FDPS | Phase 1 | Chondrosarcoma | May 2028 |
| University of Florida | Zoledronic acid Farnesyl diphosphate synthase inhibitor | FDPS | Phase 1 | Neuroblastoma | Feb 2030 |
| Qilu Hospital of Shandong University | zoledronic acid Farnesyl diphosphate synthase inhibitor | FDPS | Phase 1 | Cancer of Stomach, Adenocarcinoma | – |
Neuroblastoma (2) Bone Loss (2) Postmenopausal Osteoporosis (2) Sickle Cell Disease (1) Breast Cancer Triple Negative Breast Cancer (1) Osteogenesis Imperfecta (1) Congenital Dyserythropoietic Anemia (CDA) (1) Beta Blocker Toxicity (1) MDR-TB (1) HIV Infected Individuals (1) Critical Illness (1) Sarcoma (1)
small molecule (21), mixed (2), other (1), antibody (1)
Wake Forest University Health Sciences (2) National Taiwan University Hospital (2) University of Florida (1) University of California, Davis (1) Harbin Medical University (1) Hospital for Special Surgery, New York (1) Institute of Hematology & Blood Diseases Hospital, China (1) Sherief Abd-Elsalam (1) Shanghai Pulmonary Hospital, Shanghai, China (1) Hadassah Medical Organization (1) Australian and New Zealand Intensive Care Research Centre (1) Emory University (1) UNICANCER (1) Aarhus University Hospital (1) University of Aarhus (1) St. Louis University (1) National Institute of Allergy and Infectious Diseases (NIAID) (1) Odense University Hospital (1) AUVA Traumazentrum Vienna Site UKH Meidling (1) Qilu Hospital of Shandong University (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.